Signed a contract with Quantum Genomics, expecting new treatment options and extended life expectancy
Dong Wha Pharm (CEO Jun-ha Yoo) will supply’Firibastat’, a drug for resistant hypertension from Quantum Genomics in France, to Korea.
Dong Wha Pharm signed an exclusive license agreement for the development and sales of Pirivastat in Korea, which is being developed by Quantum Genomics, an innovative new drug developer based in Paris, France, established based on research by Paris-Descartes University and the National Institute of Health I said recently.
Resistant hypertension is hypertension that is poorly controlled by the administration of three or more hypertensive drugs, including diuretics. This is true of 10 to 20% of all hypertensive patients. Recently, the proportion of patients who use three or more drugs in combination is steadily increasing, which is a necessity for the development of various treatments.
As there is currently no adequate treatment for resistant hypertension, Pirivastat is being developed with the goal of approval by the US FDA, and when commercialized, it is expected to contribute to prolonging the life expectancy of hypertensive patients by presenting a new treatment option for patients with resistant hypertension.
‘Pirivastat’ is a new drug candidate in the brain aminopeptidase A inhibitor (BAPAI, Brain Aminopeptidase A inhibitor) family. It lowers blood pressure by inhibiting the production of angiotensin III in the brain’s renin-angiotensin system (Brain RAS, Renin Angiotensin System). And it is being developed as a treatment for resistant hypertension and heart failure, which has a triple action of diuretic and heartbeat control.
Currently, Pirivastat is undergoing phase 3 clinical trials in patients with resistant hypertension in the United States, Europe and South America. This year, a global phase 3 clinical trial, including Korean patients, is also scheduled to commence.
In addition, a global phase 2 clinical study in progress in patients with heart failure is expected to be announced in the next year. Dong Wha Pharm plans to develop and commercialize Pirivastat exclusively in Korea, as well as participate in global clinical research.
Dong Wha Pharm’s CEO Joon-Ha Yoo expressed joy that he had the opportunity to develop a treatment for resistant hypertension and heart failure through this contract. CEO Yoo said, “Based on Dongwha Pharm’s R&D capabilities, it will be a great opportunity to become a new leader in the hypertension drug market of KRW 1.4 trillion.” Starting with this contract, the new drug pipeline through active open innovation in the future We will focus on securing.”
The CEO of Quantum Genomics also expressed expectations for developing a partnership with Dong Wha Pharm. CEO Jean-Philip Millon said, “We are pleased to develop Pirivastat with Dong Wha Pharm, which has a long tradition, excellent R&D capabilities and sales power. I think Donghwa Pharm is the best partner for the development of Pirivastat.”
Copyright holder © Prohibition of unauthorized reproduction and redistribution